Replies to post #181897 on Biotech Values

[WID]

AVNR positive results from its phase 2 clinical trial of AVP-923 for treatment of agitation in patients with Alzheimer's disease may put a little pressure on ACAD for it ADP drug indication.

According to what AVNR said today in its press release, it seems that AVP-923 is very affective. Here is what the company said:"Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression domain score of the neuropsychiatric inventory (NPI) compared to placebo (p=0.00008). The reduction in agitation was observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design."

If it is true as AVNR said, ACAD might be couple years behind AVNR in this indication. However, I don't know the difference between treatment of agitation in patients with Alzheimer's disease and ADP.

Please comments.

[rogerm]

AVP-923 is basically Mucinex DM. Both are supplying 30 mg of a slow release DM with a relatively inert ingredient. AVNR's problem is it needs to persuade insurances to pay 100 x more for AVP923 than it would for the generic otc cough med. A possible problem is bid dosing in memory impaired patients who might also buy the otc med when they come down with the flu. That would double their dose of prescribed DM. http://www.walmart.com/ip/Mucinex-DM-600-Mg-Guaifenesin-30-Mg-Dextromethorphan-Hbr-Extended-Release-Bi-Layer-Tablets-Expectorant-Cough-Suppressant-20-Ct/3514429